X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (56) 56
index medicus (48) 48
humans (43) 43
female (37) 37
breast cancer (22) 22
chemotherapy (19) 19
cancer (17) 17
middle aged (15) 15
adult (12) 12
trastuzumab (12) 12
breast neoplasms - drug therapy (11) 11
breast neoplasms - pathology (10) 10
mutation (10) 10
breast neoplasms - genetics (9) 9
triple negative breast neoplasms - drug therapy (9) 9
triple negative breast neoplasms - genetics (9) 9
triple-negative breast cancer (9) 9
aged (8) 8
article (8) 8
brca1 (8) 8
care and treatment (8) 8
medicine & public health (8) 8
metastasis (8) 8
neoplasm staging (8) 8
triple negative breast neoplasms - pathology (8) 8
tumors (8) 8
antineoplastic agents - therapeutic use (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
breast neoplasms - therapy (7) 7
carboplatin (7) 7
health aspects (7) 7
survival (7) 7
adjuvant chemotherapy (6) 6
analysis (6) 6
cyclophosphamide (6) 6
dna damage (6) 6
genetic aspects (6) 6
homologous recombination (6) 6
neoadjuvant therapy (6) 6
prognosis (6) 6
research (6) 6
dna repair (5) 5
expression (5) 5
heart failure (5) 5
her2 (5) 5
neoadjuvant chemotherapy (5) 5
patients (5) 5
poly polymerase (5) 5
receptor, erbb-2 - genetics (5) 5
risk factors (5) 5
sensitivity (5) 5
stem cells (5) 5
therapy (5) 5
tumor-infiltrating lymphocytes (5) 5
biotechnology (4) 4
brca1 protein - genetics (4) 4
brca2 protein - genetics (4) 4
breast neoplasms (4) 4
breast neoplasms - diagnosis (4) 4
breast neoplasms - metabolism (4) 4
cancer therapies (4) 4
cell line, tumor (4) 4
combination (4) 4
congestive-heart-failure (4) 4
development and progression (4) 4
double-blind (4) 4
gene expression (4) 4
genes, brca1 (4) 4
germ-line mutation (4) 4
hematology, oncology and palliative medicine (4) 4
inhibition (4) 4
medical colleges (4) 4
metastases (4) 4
neoplasm metastasis (4) 4
paclitaxel (4) 4
parp inhibitors (4) 4
phase-ii (4) 4
receptor, erbb-2 - metabolism (4) 4
receptors, estrogen - metabolism (4) 4
subtypes (4) 4
surgery (4) 4
treatment outcome (4) 4
trial comparing doxorubicin (4) 4
triple negative breast neoplasms - metabolism (4) 4
adjuvant treatment (3) 3
american society (3) 3
animals (3) 3
anthracyclines (3) 3
anthracyclines - adverse effects (3) 3
antineoplastic agents - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
biomarkers, tumor - analysis (3) 3
biopsy (3) 3
brca1 protein (3) 3
brca2 (3) 3
breast (3) 3
breast cancer subtypes (3) 3
cancer patients (3) 3
capecitabine (3) 3
carboplatin - administration & dosage (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 10/2017, Volume 23, Issue 19, pp. 5687 - 5695
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 11/2010, Volume 56, Issue 20, pp. 1644 - 1650
Objectives: The purpose of this study was to examine treatment practices for cancer therapy-associated decreased left ventricular ejection fraction (LVEF)... 
Heart failure | Left ventricular dysfunction | Anthracyclines | Chemotherapy | Cancer | ADJUVANT CHEMOTHERAPY | heart failure | CARDIAC & CARDIOVASCULAR SYSTEMS | RISK-FACTORS | TRASTUZUMAB | ADULTS | left ventricular dysfunction | chemotherapy | HER2-POSITIVE BREAST-CANCER | TRIAL COMPARING DOXORUBICIN | LYMPHOMA | cancer | anthracyclines | CONGESTIVE-HEART-FAILURE | HER2 | PLUS | Anthracyclines - adverse effects | Prognosis | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Heart Ventricles - diagnostic imaging | Ventricular Dysfunction, Left - chemically induced | Dose-Response Relationship, Drug | Young Adult | Antibodies, Monoclonal, Humanized | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Antineoplastic Agents - adverse effects | Ultrasonography | Adult | Female | Retrospective Studies | Adrenergic beta-Antagonists - therapeutic use | Risk Factors | Stroke Volume - drug effects | Ventricular Dysfunction, Left - physiopathology | Neoplasms - drug therapy | Ventricular Dysfunction, Left - drug therapy | Heart Ventricles - physiopathology | Aged | Anthracyclines - therapeutic use | Angiotensin Receptor Antagonists - therapeutic use | Trastuzumab | Breast cancer | Heart attacks | Drug therapy | Cancer therapies | Beta blockers | Leukemia | Index Medicus | Abridged Index Medicus | Angiotensin receptors
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2017, Volume 35, Issue 10, pp. 1139 - 1139
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. CT022 - CT022
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 2019, Volume 25, Issue 9, pp. 2717 - 2724
Purpose: To assess talazoparib activity in germline BRCA1/2 mutation carriers with advanced breast cancer. Patients and Methods: ABRAZO (NCT02034916) was a... 
TRIAL | OLAPARIB | RIBOSE POLYMERASE INHIBITORS | THERAPY | ONCOLOGY | SAFETY | DNA | ADVANCED OVARIAN | PARP | CARRIERS
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 4749 - 4749
Journal Article
Journal of the National Comprehensive Cancer Network : JNCCN, ISSN 1540-1405, 05/2019, Volume 17, Issue 55, pp. 552 - 555
Advances in molecular testing have ushered in the new era of precision medicine. The 2018 publication of the TAILORx trial helped refine the use of genetic... 
ONCOLOGY
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 11/2018, Volume 36, Issue 31, pp. 3134 - 3134
PurposeThis multicenter phase II trial evaluated lurbinectedin (PM01183), a selective inhibitor of active transcription of protein-coding genes, in patients... 
TRABECTEDIN | ONCOLOGY | PM01183 | DNA | Index Medicus | ORIGINAL REPORTS
Journal Article
Current Breast Cancer Reports, ISSN 1943-4588, 3/2017, Volume 9, Issue 1, pp. 52 - 59
Since the identification of the BRCA1 and BRCA2 genes over two decades ago, considerable progress has been made in elucidating the role of defective DNA repair... 
Medicine & Public Health | Platinum | PARP inhibitors | Internal Medicine | Oncology | HRD | BRCA1 | Homologous recombination DNA repair | BRCA2 | Surgical Oncology | BRCA ness | BRCAness | Biotechnology | Medical colleges | Sugars | Monosaccharides
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2018, Volume 36, Issue 31, pp. 3126 - 3133
PurposeThere are currently no targeted therapies approved for triple-negative breast cancer (TNBC). A tumor necrosis factor (TNF)-based gene expression... 
TARGETED THERAPIES | CARBOPLATIN | ONCOLOGY | DRUG DEVELOPMENT | IAPS | MODEL | ADAPTIVE RANDOMIZATION | PATHOLOGICAL COMPLETE RESPONSE
Journal Article
Future Oncology, ISSN 1479-6694, 02/2017, Volume 13, Issue 4, pp. 307 - 320
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.